drugset / Trial / NCT06990399
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Timeline
- Start
- 2025-07-30
- Primary completion
- 2027-04
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KSI-101 | Unknown | 5 mg | Intravitreal |
| Subject | KSI-101 | Unknown | 10 mg | Intravitreal |